| Schedule of Basic and Diluted Net Loss per Share Attributable to Common Stockholders |
The
following table sets forth the computation of the Company’s basic and diluted net earnings (loss) per share attributable to common
stockholders (in thousands, except share and per share data):
Schedule of Basic and Diluted Net Loss per Share Attributable to Common Stockholders
| | |
2025 | | |
2024 | |
| | |
For years ended December 31, | |
| | |
2025 | | |
2024 | |
| Net loss | |
$ | (10,536 | ) | |
$ | (17,759 | ) |
| Weighted average common shares outstanding, basic and diluted | |
| 10,171,921 | | |
| 5,516,334 | |
| Net loss per share, basic and diluted | |
$ | (1.04 | ) | |
$ | (3.22 | ) |
|
| Schedule of Anti-dilutive Securities Excluded from Computation of Earnings per Share |
The
following table sets forth securities that were anti-dilutive for diluted earnings per share (“EPS”) for the periods presented but which could potentially dilute
EPS in the future:
Schedule of Anti-dilutive Securities Excluded from Computation of Earnings per Share
| December 31, | |
2025 | | |
2024 | |
| Common stock warrants | |
| 2,269,356 | | |
| 2,269,356 | |
| Common stock options and RSUs | |
| 2,299,218 | | |
| 1,808,718 | |
| Unit Purchase Options | |
| 20,182 | | |
| 20,182 | |
| Series B-2 convertible preferred stock | |
| 2,896,650 | | |
| 14,318,632 | |
| Series B-3 convertible preferred stock | |
| 9,315,909 | | |
| - | |
| Series C convertible preferred stock | |
| 17,153,187 | | |
| - | |
| Series D convertible preferred stock | |
| 4,831,185 | | |
| - | |
| Convertible notes | |
| 6,006,345 | | |
| 5,384,615 | |
| Total | |
| 44,792,032 | | |
| 23,801,503 | |
| Anti-dilutive securities | |
| 44,792,032 | | |
| 23,801,503 | |
|